Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?
- First Online:
- Cite this article as:
- McMahon, M.S. HSS Jrnl (2009) 5: 159. doi:10.1007/s11420-009-9115-x
- 67 Downloads
Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.